Person:
MESUT, ÖMER ÇAĞATAY

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

MESUT

First Name

ÖMER ÇAĞATAY

Name

Filters

2022 - 20242
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Does gonadotropin dose adjustment in inadequate ovarian response during controlled ovarian hyperstimulation improve the live birth rates of patients with diminished ovarian reserve?
    (Oxford Univ Press, 2022-07-01) Mesut, O. C.; MESUT, ÖMER ÇAĞATAY; Gürbüz, T. B.; GÜRBÜZ, TANSU BAHAR; Aslan, K.; ASLAN, MÜNİR KİPER; Uncu, G.; UNCU, GÜRKAN; Kasapoğlu,; KASAPOĞLU, IŞIL; Tıp Fakültesi; Kadın Hastalıkları ve Doğum Ana Bilim Dalı
  • Thumbnail Image
    Publication
    The effect of the gonadotropin dose increment during controlled ovarian hyperstimulation on live birth rates of POSEIDON group 3-4 patients
    (Bursa Uludağ Üniversitesi, 2024-06-12) Aslan, Kiper; Kasapoğlu, Işıl; Mesut, Çağatay; Gürbüz, Tansu Bahar; Çakır, Cihan; Avcı, Berrin; Uncu, Gürkan; ASLAN, MÜNİR KİPER; KASAPOĞLU, IŞIL; MESUT, ÖMER ÇAĞATAY; GÜRBÜZ, TANSU BAHAR; ÇAKIR, CİHAN; AVCI, BERRİN; UNCU, GÜRKAN
    This retrospective study seeks to explore whether modifying the gonadotropin dose in cases of poor ovarian response during controlled ovarian hyperstimulation contributes to improved live birth rates in Poseidon Group 3-4 patients. The study took place at a tertiary level university. The electronic database spanning 2012-2021 was scrutinized to identify patients with diminished ovarian reserve (DOR) who underwent intra-cytoplasmic sperm injection – embryo transfer (ICSI-ET). Diminished ovarian reserve was determined using the POSEIDON criteria. Patients were categorized into two groups based on whether dose adjustment was implemented during the initial ultrasound assessment in controlled ovarian hyperstimulation (COH). There were 188 patients in the dose adjustment (DA) group and 310 patients in the fixed-dose (FD) group. The demographic parameters were similar between the groups. The started gonadotropin dose was similar in both groups (300 IU). The median dose adjustment on the first control was +75 IU in the DA group. The follicle output rates, follicle to oocyte indexes, and the embryology parameters were comparable between the groups. The positive pregnancy rate was 19.7% (36/188) in the DA group vs. 19.1% (61/310) in the FD Group (p=0.4). The primary outcome of the study; live birth rates were 12% in the DA group vs. 9% in the FD group, and the results were statistically similar (p=0.3). Our research revealed that adjusting the gonadotropin dose in cases of inadequate ovarian response during COH results in comparable live birth rates to those observed in the fixed-dose group. For patients exhibiting an inadequate response, dose adjustment may be deemed necessary.